Early markers of myocardial injury: cTnI is enough

Area of Science:

• Cardiology
• Biomarker Research
• Acute Coronary Syndromes

Background:

• Early diagnosis of acute coronary syndrome (ACS) is crucial for patient outcomes.
• Cardiac biomarkers play a key role in the early identification of myocardial injury.
• Comparing the performance of novel biomarkers against established ones is essential.

Purpose of the Study:

• To compare the early diagnostic and prognostic performance of a highly sensitive cardiac troponin I (cTnI) assay versus heart-type fatty acid binding protein (H-FABP).
• To evaluate the utility of these biomarkers in the initial hours following acute coronary syndrome symptom onset.

Main Methods:

• Serum samples from 293 patients with suspected ACS were analyzed.
• Assays used included the Abbott Architect cTnI assay and the H-FABP assay.
• Diagnostic and prognostic values were assessed using admission samples taken within 24 hours of symptom onset, with a 6-month follow-up for mortality and reinfarction.

Main Results:

• For samples taken within 6 hours of symptom onset, cTnI showed a higher area under the receiver operating characteristic curve (AUC) than H-FABP (0.908 vs. 0.855).
• For samples taken between 6-24 hours, cTnI's AUC was significantly higher (0.995 vs. 0.849, p=0.002).
• Multivariate analysis indicated that cTnI, but not H-FABP, independently predicted adverse events in all patients and in those presenting within 6 hours.

Conclusions:

• Highly sensitive cTnI assays provide robust early diagnostic and prognostic information for acute coronary syndrome.
• H-FABP does not appear to offer additional clinical value beyond highly sensitive cTnI, even in the critical early presentation window.
• The findings support the primary role of highly sensitive cTnI in the early management of patients with suspected ACS.